Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $81.1538.

Several equities research analysts have issued reports on the company. Evercore set a $91.00 target price on Vera Therapeutics in a research report on Friday, May 15th. Wedbush reiterated a “neutral” rating and issued a $34.00 price target on shares of Vera Therapeutics in a research report on Monday, August 17th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Finally, Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a report on Wednesday, July 8th.

Vera Therapeutics Price Performance

VERA opened at $35.28 on Wednesday. The firm has a 50-day moving average price of $36.34 and a 200-day moving average price of $37.86. Vera Therapeutics has a twelve month low of $21.15 and a twelve month high of $56.05. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of -6.02 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the previous year, the firm earned ($1.20) EPS. Equities analysts expect that Vera Therapeutics will post -6.43 EPS for the current year.

Insider Activity

In related news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the stock. UBS Group AG increased its stake in Vera Therapeutics by 27.9% during the 4th quarter. UBS Group AG now owns 207,289 shares of the company’s stock valued at $10,497,000 after purchasing an additional 45,214 shares in the last quarter. E. Ohman J or Asset Management AB lifted its stake in shares of Vera Therapeutics by 99.5% in the second quarter. E. Ohman J or Asset Management AB now owns 85,777 shares of the company’s stock worth $3,681,000 after buying an additional 42,787 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares in the last quarter. Swedbank AB grew its holdings in shares of Vera Therapeutics by 142.4% during the fourth quarter. Swedbank AB now owns 121,200 shares of the company’s stock valued at $6,138,000 after buying an additional 71,200 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Vera Therapeutics by 136.5% during the first quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock valued at $18,397,000 after buying an additional 263,900 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.